Panel Discussion: Balancing Innovation & Compliance in Diagnostic Testing Amidst the Final LDT Rule to Ensure Patient Access to Great Drugs
Time: 8:30 am
day: Day Two AM
Details:
- Debating the positive and negative aspects of the Final LDT Rule for liquid biopsy innovation
- Understanding the responsibilities for drug-diagnostic partnerships in ensuring swift approvals
- How can we minimize financial and temporal burdens of complex approvals in the US?
